EXEL / Farallon to launch proxy fight at biotech Exelixis: WSJ

Exelixis (EXEL) misses third-quarter 2023 earnings and sales estimates but tightens its annual revenue guidance and increases its R&D guidance. more_horizontal

While the top- and bottom-line numbers for Exelixis (EXEL) give a sense of how the business performed in the quarter ended September 2023, it could be more_horizontal

Exelixis (EXEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the sto more_horizontal

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Exelixis (EXEL) and Techne (TECH). But more_horizontal

The Federal Reserve's decision on interest rates will impact the short-term outlook of the economy. However, even with higher-for-longer interest rate more_horizontal

Exelixis (EXEL) enters into a license agreement with Insilico Medicine for ISM3091, a potentially best-in-class USP1 inhibitor. more_horizontal

Exelixis Inc. EXEL, -0.54% is licensing the global rights to develop and commercialize an investigational cancer treatment that was derived from Insil more_horizontal

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL) or Illumina (ILMN). But whi more_horizontal